One of the biggest challenges in cancer medicine today is selecting the right treatment regimen for the right patient taking into account multiple therapies and patient variability (Safety & Efficacy). Sequencing tumours alone does not solve the problem of finding the right treatment regimen for cancer patients, while many patients take concomitant medications for comorbid conditions. BioXplor's network pharmacology system is being developed to uniquely prioritize drug combinations based on safety and efficacy insights, while avoiding drug-drug interactions which can lead to serious adverse events.
BioXplor's network pharmacology analysis uniquely prioritizes treatments for complex diseases like cancer based on safety and efficacy insights from multiple unstructured and disparate data sources. Synergistic Drug Combinations can be more effective and less toxic with reduced drug resistance than monotherapies. Antagonistic Drug Interactions can cause severe adverse drug reactions in patients. BioXplor's system uses an evidence-baed approach to prioritize these treatments and detect potential issues with drug combinations and interactions.
Network Pharmacology Analysis
Request Case Studies
1 Drug Combinations for COVID-19
Prioritization of synergistic anti-inflammation and anti-viral drug combinations based on safety and efficacy profiles, including combinations by stage of development from pre-clinical to post-approval.
2 Drug Combinations for Lipedema
Pathway analysis to identify novel drug targets for a Lipedema, a rare fat disorder, and the prioritization of safe and effective treatments with evidence supporting Lipedema treatment.
3 Drug Combinations for ETP-ALL
Repositioning of an approved drug combination to a very rare and aggressive from of leukemia (ETP-ALL) using human interactome-based network pharmacology.